Accéder au contenu
Merck

Y102

YC-1

soluble guanylyl cyclase activator, powder

Synonyme(s) :

3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Formule empirique (notation de Hill) :
C19H16N2O2
Numéro CAS:
Poids moléculaire :
304.34
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Form:
powder
Quality level:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

YC-1, powder

SMILES string

OCc1ccc(o1)-c2nn(Cc3ccccc3)c4ccccc24

InChI

1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2

InChI key

OQQVFCKUDYMWGV-UHFFFAOYSA-N

form

powder

color

white to yellow

solubility

DMSO: 10 mg/mL, H2O: insoluble

Quality Level

Gene Information

human ... PDE5A(8654)

Catégories apparentées

Application

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:
  • to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs)
  • to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming units
  • to study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway.

Biochem/physiol Actions

NO (nitric oxide)-independent activator of soluble guanylyl cyclase.
YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Vehicle-dependent effects of sphingosine 1-phosphate on plasminogen activator inhibitor-1 expression
Takahashi C, et al.
Journal of Atherosclerosis and Thrombosis, 37663-37663 (2017)
Arnaud Courtois et al.
Environmental health perspectives, 116(10), 1294-1299 (2008-10-23)
Because pulmonary circulation is the primary vascular target of inhaled particulate matter (PM), and nitric oxide is a major vasculoprotective agent, in this study we investigated the effect of various particles on the NO-cyclic guanosine monophosphate (cGMP) pathway in pulmonary
F N Ko et al.
Blood, 84(12), 4226-4233 (1994-12-15)
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] inhibited the aggregation of and ATP release from washed rabbit platelets induced by arachidonic acid (AA), collagen, U46619, platelet-activating factor (PAF), and thrombin in a concentration-dependent manner. YC-1 also disaggregated the clumped platelets caused by these inducers. The
Zong-Tao Chai et al.
PloS one, 8(10), e77957-e77957 (2013-11-07)
microRNAs (miRNAs) have been reported to regulate angiogenesis by down-regulating the expression of pro-angiogenic or anti-angiogenic factors. The aims of this study were to investigate whether miR-26a inhibited angiogenesis by down-regulating vascular endothelial growth factor A (VEGFA) and its clinical
Hypoxia-stressed cardiomyocytes promote early cardiac differentiation of cardiac stem cells through HIF-1$\alpha$/Jagged1/Notch1 signaling
Wang K, et al.
Acta Pharmaceutica Sinica. B, 8(5), 795-804 (2018)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique